Trending Stocks Ticker by Stock Target Advisor
Sumitomo Mitsui Trust Holdings (OTC: CMTDF) has acquired additional shares in Intellia Therapeutics (NSD:NTLA) during the fourth quarter, according to the company’s latest filing with the Securities and Exchange Commission. The investor now owns 2,976,002 shares, an increase of 0.4% or 12,074 shares. The stake is valued at $103,833,000 and represents approximately 3.78% of Intellia Therapeutics’ total worth. Other institutional investors, including Wipfli Financial Advisors LLC and Koshinski Asset Management Inc., have also recently purchased shares in the company. Intellia Therapeutics, a biotechnology company focused on genome editing and developing therapies using CRISPR technology, has received ratings from equities research analysts. One analyst has rated the stock as “sell”, three as “hold”, and 15 as “buy”, resulting in an average rating of “strong buy” and a consensus target price of $86.82. Intellia Therapeutics stock is currently trading at $34.58 average of $43.29. The company reported a negative return on equity of 48.70% and negative net margin of 909.78% during its last quarterly earnings, which were in line with analysts’ expectations.
NTLA Stock Analysis & Forecast
Intellia Therapeutics Inc has an average analyst target price of USD 93.97 based on the forecasts of 28 analysts, indicating a strong buy rating for the company. However, Stock Target Advisor’s analysis is bearish with 2 positive signals and 6 negative signals. The current stock price for Intellia Therapeutics Inc is USD 39.11, which reflects an increase of 8.76% over the past week, an increase of 2.09% over the past month, but a decrease of 37.92% over the past year.
Company background
Intellia Therapeutics is a genome editing company that is focused on developing curative therapeutics for a range of diseases. Its programs include in vivo treatments for transthyretin amyloidosis, hereditary angioedema, alpha-1 antitrypsin deficiency-liver disease, alpha-1 antitrypsin deficiency-lung disease, and CD30+ lymphomas. It also has an ex vivo pipeline for acute myeloid leukemia and is developing engineered cell therapies for cancers and autoimmune diseases. Intellia Therapeutics was founded in 2014 and is based in Cambridge, Massachusetts.
